KFS
AXSM icon

Kelly Financial Services’s Axsome Therapeutics AXSM Stock Holding History

Kelly Financial Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-41
Closed -$4.24K – 585
2019
Q4 		$4.24K Buy
+41
New +$1.66K ﹤0.01% 325
2019
Q3 		– Sell
-160
Closed -$4.12K – 554
2019
Q2 		$4.12K Buy
+160
New +$3.21K ﹤0.01% 306

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kelly Financial Services's AXSM Position: Q1 2020 in Review

Kelly Financial Services sold out of Axsome Therapeutics (AXSM) in Q1 2020, closing a stake of 41 shares — an estimated $4.24K sold.

Kelly Financial Services first reported a position in AXSM in Q2 2019 and held it in 2 quarters. The position peaked at $4.24K in Q4 2019. 163 funds tracked by Wall St. Rank hold AXSM as of Q1 2020.

  • Kelly Financial Services reported no remaining Axsome Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Kelly Financial Services sold 41 Axsome Therapeutics shares in Q1 2020, an estimated $4.24K.
  • Kelly Financial Services first reported a position in Axsome Therapeutics in Q2 2019 and held it in 2 quarters.
  • Kelly Financial Services's Axsome Therapeutics position peaked at $4.24K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2020.

Based on Kelly Financial Services's 13F filing for Q1 2020, filed 17 Jul 2024.